Vitrolife AB (publ) (OM: VITR)
Health Care · Biotechnology · SE
Skr95.05
-0.05% today · -31.3% 1Y
Vitrolife AB (publ) (OM: VITR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.36B and employs 1,103 people.
Over the last twelve months the share price has lost 31.3%, trading between 84.00 and 153.50.
Tweenvest scores Vitrolife AB (publ) across four factors: quality 69/100, value 84/100, growth 46/100, dividend 65/100. Its strongest factor is value.
VITR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.36B
- Revenue (TTM)
- $349.77M
- P/E
- —
- EPS
- -36.80
- Dividend yield
- 1.20%
- Beta (5Y)
- 1.71
- 52-week high
- Skr153.50
- 52-week low
- Skr84.00
- Avg volume (3M)
- —
- Shares outstanding
- 135.42M
- Employees
- 1,103
- Next earnings
- —
About Vitrolife AB (publ)
Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such as oocyte retrieval needles, sperm processing solutions, specialized in vitro fertilization media and oils, and micromanipulation pipettes. The company also provides general labware, incubators, cryopreservation products, and systems for preimplantation genetic testing. Furthermore, Vitrolife delivers advanced equipment, including the EmbryoScope and Primo Vision time-lapse systems, along with dedicated dishes and evaluation software for these platforms. Their technology portfolio extends to Octax laser and imaging systems, as well as environmental monitoring solutions like log and guard systems and wireless sensors. With its headquarters located in Gothenburg, Sweden, Vitrolife maintains a significant international presence, operating across Europe, the Middle East, and Africa; Asia; Japan and the Pacific; and both North and South America. Founded in 1994, the company was initially known as Scandinavian IVF Science before officially changing its name to Vitrolife AB (publ) in 1998.
- ISIN
- SE0011205202
- Founded
- 1989
- Listed since
- Jun 28, 2001
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.